Clinical stage oncology company Revolution Medicines, Inc. made its debut in the stock market on Thursday and was welcomed by Wall Street. The stock skyrocketed 85% after underwriters priced the initial public offering at the top end of a revised range. The California-based company sold 14 million shares priced at $17 each to raise $238 … Continue reading “Revolution Medicines Inc. Explodes on First Day of Trading”
